Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04592913 · ClinicalTrials.gov registry record · Phase 3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
A Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 957
- Enrollment target
- 20
- Study locations
NCT04592913: Active Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction, sponsored by AstraZeneca.
NCT04592913 is a Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 957 participants, roughly in line with the 887-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04592913, a Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 957 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
Primary Outcome
EFS is the time from date of randomization until the date of disease progression or death.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG FLOT chemotherapy
Study Locations (20)
California
- Research Site - Duarte
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Sylmar
Other
- Research Site - Buenos Aires
- Research Site - Ciudad Autonoma Buenos Aires
- Research Site - Ciudad de Buenos Aires
- Research Site - Ciudad de Buenos Aires
Florida
- Research Site - St. Petersburg
- Research Site - Tallahassee
- Research Site - West Palm Beach
New York
- Research Site - New York
- Research Site - Rochester
Texas
- Research Site - Dallas
- Research Site - Lancaster
Indiana
- Research Site - Fort Wayne
Kentucky
- Research Site - Louisville
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 957 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2027-09-27 |
| Phase | Phase 3 |
What the registry record for NCT04592913 still lists
NCT04592913 is an interventional study that assigns participants to a tested intervention. The registered 957 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 887-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target.
The record links to 2 conditions, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT04592913 names 20 study sites across 10 states, led by California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT04592913 about?
NCT04592913 is a clinical study titled "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer". This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
What is the current status of trial NCT04592913?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 957 participants. The study started on 2020-11-17. Estimated completion is 2027-09-27.
What conditions does trial NCT04592913 study?
This clinical trial studies the following conditions: Gastrointestinal Neoplasms, Esophagogastric Junction.
What interventions are being tested in trial NCT04592913?
The interventions under investigation include: Durvalumab (DRUG), FLOT chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04592913?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04592913 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04592913's enrollment target sits among peer trials
957 2nd of 12 the highest of 12 other Gastrointestinal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
RECRUITING
-
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI